HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (20) Citing Articles via Google Scholar Google Scholar Articles by Barnes, P. J. Search for Related Content PubMed PubMed Citation Articles by Barnes, P. J.

Scientific rationale for using a single inhaler for asthma control

National Heart and Lung Institute, Imperial College London, UK.

CORRESPONDENCE: P. J. Barnes, Section of Airway Disease, National Heart & Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK. Fax: 44 2073515675. E-mail: p.j.barnes{at}imperial.ac.uk

Keywords: Asthma exacerbation, combination therapy, corticosteroid, inflammation, long-acting ß₂-agonist, mast cell

Received: June 19, 2006
Accepted September 26, 2006

Clinical trials have recently demonstrated that using a budesonide/formoterol combination inhaler as regular maintenance treatment twice daily but also as a rescue therapy for breakthrough symptoms can provide more effective control of asthma, particularly in reducing exacerbations, than using a short-acting ß₂-agonist or formoterol as rescue therapy. This suggests that the corticosteroid component of the combination therapy plays an important role in rescue therapy.

Formoterol as a rescue therapy is effective in relieving symptoms by relaxing airway smooth muscle but is also likely to have important inhibitory effects on mast cells, plasma exudation and neutrophilic inflammation.

Inhaled corticosteroids have much more rapid suppressing effects on airway inflammation than previously recognised and the increased dose used as rescue therapy may prevent the increase in airway inflammation that occurs during the evolution of an exacerbation, thus preventing its development.

It is likely that the molecular interactions between ß₂-agonists and corticosteroids also enhance the effect of the combination therapy as rescue therapy. There is now a strong scientific rationale for single inhaler therapy in asthma, but more research is now needed to better understand the mechanisms involved.

This article has been cited by other articles:

				J. L. Black, B. G. G. Oliver, and M. Roth Molecular Mechanisms of Combination Therapy With Inhaled Corticosteroids and Long-Acting {beta}-Agonists Chest, October 1, 2009; 136(4): 1095 - 1100. [Abstract] [Full Text] [PDF]

				A. Papi, G. Caramori, I. M. Adcock, and P. J. Barnes Rescue Treatment in Asthma: More Than As-Needed Bronchodilation Chest, June 1, 2009; 135(6): 1628 - 1633. [Abstract] [Full Text] [PDF]

				A. C. Plint, D. W. Johnson, H. Patel, N. Wiebe, R. Correll, R. Brant, C. Mitton, S. Gouin, M. Bhatt, G. Joubert, et al. Epinephrine and Dexamethasone in Children with Bronchiolitis N. Engl. J. Med., May 14, 2009; 360(20): 2079 - 2089. [Abstract] [Full Text] [PDF]

				B. Lindmark Review: Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 279 - 299. [Abstract] [PDF]

				A. A. Litonjua, J. Lasky-Su, K. Schneiter, K. G. Tantisira, R. Lazarus, B. Klanderman, J. J. Lima, C. G. Irvin, S. P. Peters, J. P. Hanrahan, et al. ARG1 Is a Novel Bronchodilator Response Gene: Screening and Replication in Four Asthma Cohorts Am. J. Respir. Crit. Care Med., October 1, 2008; 178(7): 688 - 694. [Abstract] [Full Text] [PDF]